Compare Becton Dickinson and Co (BDX) vs Lemonade Inc (LMND) Price & Performance

BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.

The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.

Lemonade (LMND) trades at $70.62, up 0.16% on the day, with a bullish technical signal from moving averages and ADX indicators. Revenue growth is robust, increasing from $257M in 2022 to $738M in 2025, while net losses are narrowing, with the net margin improving from -116.02% to -22.43% over the same period. Recent news highlights expansion into new states and a renegotiated reinsurance program, improving cost structure and capital efficiency.

The outlook is mixed; strong revenue growth and narrowing losses present a long-term opportunity, but the stock trades above the consensus price target of $67.00, with 40% of analysts rating it a sell. Key risks include persistent unprofitability, high valuation multiples, and execution challenges in scaling the AI-driven insurance model. Positive cash flow from operations is projected for 2026, a potential inflection point.